Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells by Prabakaran, T et al.
Title Mannose 6-phosphate receptor and sortilin mediatedendocytosis of α-galactosidase A in kidney endothelial cells
Author(s) Prabakaran, T; Nielsen, R; Satchell, SC; Mathieson, PW; Feldt-Rasmussen, U; Sørensen, SS; Christensen, EI
Citation PLoS ONE, 2012, v. 7 n. 6
Issued Date 2012
URL http://hdl.handle.net/10722/195516
Rights Creative Commons: Attribution 3.0 Hong Kong License
Mannose 6-Phosphate Receptor and Sortilin Mediated
Endocytosis of a-Galactosidase A in Kidney Endothelial
Cells
Thaneas Prabakaran1, Rikke Nielsen1, Simon C. Satchell2, Peter W. Mathieson2, Ulla Feldt-Rasmussen3,
Søren S. Sørensen4, Erik I. Christensen1*
1Department of Biomedicine, Aarhus University, Aarhus, Denmark, 2Academic Renal Unit, University of Bristol, Bristol, United Kingdom, 3Department of Medical
Endocrinology, Rigshospitalet, Copenhagen, Denmark, 4Department of Nephrology P, Rigshospitalet, Copenhagen, Denmark
Abstract
Prominent vasculopathy in Fabry disease patients is caused by excessive intracellular accumulation of globotriaosylcer-
amide (GL-3) throughout the vascular endothelial cells causing progressive cerebrovascular, cardiac and renal impairments.
The vascular lesions lead to myocardial ischemia, atherogenesis, stroke, aneurysm, thrombosis, and nephropathy. Hence,
injury to the endothelial cells in the kidney is a key mechanism in human glomerular disease and endothelial cell repair is an
important therapeutic target. We investigated the mechanism of uptake of a-galactosidase A (a-Gal A) in renal endothelial
cells, in order to clarify if the recombinant enzyme is targeted to the lysosomes via the universal mannose 6-phosphate
receptor (M6PR) and possibly other receptors. Immunohistochemical localization of infused recombinant a-Gal A in a renal
biopsy from a classic Fabry disease patient showed that recombinant protein localize in the endothelial cells of the kidney.
Affinity purification studies using a-Gal A resins identified M6PR and sortilin as a-Gal A receptors in cultured glomerular
endothelial cells. Immunohistochemical analyses of normal human kidney with anti-sortilin and anti-M6PR showed that
sortilin and M6PR were expressed in the endothelium of smaller and larger vessels. Uptake studies in cultured glomerular
endothelial cells of a-Gal A labeled with fluorescence and 125I showed by inhibition with RAP and M6P that sortilin and
M6PR mediated uptake of a-Gal A. Biacore studies revealed that a-Gal A binds to human M6PR with very high affinity, but
M6PR also binds to sortilin in a way that prevents a-Gal A binding to sortilin. Taken together, our data provide evidence that
sortilin is a new a-Gal A receptor expressed in renal endothelial cells and that this receptor together with the M6PR is able to
internalize circulating a-Gal A during enzyme replacement therapy in patients with Fabry disease.
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Introduction
Fabry-Anderson disease is an X-linked lysosomal storage
disorder caused by deficient activity of the lysosomal enzyme a-
galactosidase A (a-Gal A) [1,2]. The enzyme plays a critical role in
glycosphingolipid metabolism and deficiency causes accumulation
of neutral glycosphingolipids, mainly globotriaosylceramide (GL-3)
in the endothelium, epithelial and smooth muscle cells of different
organs. The progressive GL-3 accumulations in the vascular
endothelial cells (ECs) of the skin, eye, heart, kidney, brain, and
peripheral nervous system accounts for the prominent vasculo-
pathy leading to progressive cerebrovascular, cardiac and renal
impairments and premature death [1].
End-stage renal failure occurs in some of the patients with Fabry
disease in their third to fifth decade of life, when the lysosomal GL-
3 accumulation becomes irreversible [3,4] and patients are in need
of dialysis or renal transplantation [4,5].
Enzyme replacement therapy (ERT) results in significant
clearance of GL-3 deposits throughout the vascular endothelium
[6,7]. ERT reduces the GL-3 deposits in the GECs and other renal
ECs [1,7,8,9], thereby stabilizing kidney function in patients with
Fabry nephropathy, if instituted sufficiently early [10]. Therapeu-
tic effectiveness of ERT with a-Gal A is dependent on endocytosis
by recognition of mannose 6-phosphate (M6P) residues on the
enzyme by the widely distributed cation-independent M6P
receptor/insulin-like growth II receptor [11,12,13]. Although
ERT has been demonstrated to be efficacious in treatment for
Fabry disease, there are many unanswered questions related to the
ability of recombinant proteins to target key tissues. Hence, the
effectiveness of treatment with ERT in Fabry disease needs further
clarification by investigating more cell models of different tissues
that are prominently affected in Fabry disease. Our previous
studies have already shown that the uptake of a-Gal A in proximal
tubule cells is mainly mediated by megalin, whereas in podocytes
the uptake is mediated by M6PR, megalin, and sortilin [14,15].
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In this study, we have identified two receptors, M6PR and
sortilin, as a-Gal A binding proteins important for the delivery of
a-Gal A to ECs in the human kidney. Thus, our data indicate that
circulating a-Gal A may be taken up by renal ECs by a M6PR-
and sortilin- mediated pathway during ERT in Fabry disease
patients. These data can in term be applied to other ECs in other
parts of the body.
Materials and Methods
Antibodies and proteins
Recombinant a-Gal A (agalsidase beta, Fabrazyme) and
affinity-purified rabbit polyclonal anti-human a-Gal A were
provided by Genzyme Corp. (Framingham, MA, USA). Recom-
binant receptor-associated protein (RAP) was provided by Novo
Nordisk A/S (Bagsværd, DK). Affinity purified rabbit polyclonal
anti-sortilin was generated against the ectodomain of sortilin, as
previously described [16]. Polyclonal rabbit anti-IGF-II/M6PR
3637 was a kind gift from Dr. W. Kiess, Hospital for Children and
Adolescence, University of Leipzig, Leipzig, DE. The mannose 6-
phosphate (M6P; M3655) and anti-IGF-II receptor (HPA011332)
were purchased from Sigma Aldrich (Saint Louis, MO, USA).
Recombinant human M6PR (6418-GR) containing the residues
Gln41-Asp1365 was purchased from R&D Systems. Affinity purified
soluble human sortilin was a kind gift from Dr. Claus Munck
Petersen, Department of Biomedicine, Aarhus University, Aarhus,
DK. Polyclonal rabbit anti-sortilin (ab16640) was purchased from
Abcam. Monoclonal mouse anti-human CD34, mouse anti-
human platelet endothelial cell adhesion molecule (PECAM-1),
and peroxidase-conjugated secondary antibodies were all pur-
chased from DAKO A/S (Glostrup, DK). Fluorescence-conjugat-
ed secondary antibodies were purchased from Molecular Probes
(Eugene, OR, USA). Controls for nonspecific binding were
performed with nonspecific rabbit or mouse IgG from DAKO.
Biopsy preparation
A kidney biopsy was obtained from a male Fabry patient,
37 years of age, 2 h after enzyme replacement infusion, 0.2 mg/kg
Figure 1. Uptake of a-Gal A by human kidney ECs. (A) Dual immunofluorescence staining showing a-Gal A in the glomerulus (G) in a renal
biopsy from a Fabry patient who was infused with a-Gal A 2 h before the biopsy. Localization of a-Gal A is observed in the GECs as indicated by co-
localization with CD34 (endothelial cell surface marker). Merged high power view demonstrates that a-Gal A is seen in GECs (white arrowheads) and
in podocyte (blue arrowhead) in a human glomerulus from a Fabry disease patient. Labeling for a-Gal A is also seen in the proximal tubule (PT). Scale
bar, 25 mm. (B) Peroxidase staining showing localization of a-Gal A (green arrowheads) in larger vessel ECs in a renal biopsy from a Fabry patient who
was infused with a-Gal A 2 h before the biopsy. Scale bar, 25 mm. (C) Uptake of Alexa-Fluor 546-labeled a-Gal A (red) in cultured human GECs as a
function of time at 37uC. At the indicated times, the cells were fixed and analyzed by confocal microscopy. Scale bar, 5 mm. (D) Co-localization (yellow)
of a-Gal A (red) and lysosomes (green). A merged image is shown. Scale bar, 5 mm.
doi:10.1371/journal.pone.0039975.g001
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body wt recombinant a-Gal A. Oral consent to biopsy was
obtained from the patient according to local regulations. The
biopsy was fixed and routine embedded in paraffin. Human tissue
sections were also obtained from paraffin-embedded normal
human kidneys (autopsy materials).
Immunohistochemistry
For immunoperoxidase and immunofluorescence staining,
2 mm tissue paraffin sections were cut and prepared as previously
described [17]. Immunoperoxidase staining was performed as
previously described [17]; briefly sections were incubated with
primary antibodies followed by incubation with HRP-conjugated
secondary antibody. Peroxidase labeling was visualized by
incubation with diaminobenzidine and 0.03% H2O2 for 10 min
and sections counterstained with Meier’s hematoxylin. Sections
were examined in a Leica DMR microscope equipped with a
Leica DFC320 camera. Images were transferred by a Leica TFC
Twain 6.1.0 program and processed using Adobe Photoshop 8.0.
For double immunofluorescence staining, sections were incu-
bated with primary mouse monoclonal and rabbit polyclonal
antibodies followed by Alexa Fluor conjugated anti-mouse and
anti-rabbit IgG. Staining was analyzed by confocal laser scanning
microscope (LSM510; Carl Zeiss, DE). Controls; sections were
incubated without primary antibodies or with nonspecific IgG.
Cells
The human glomerular endothelial cells (GECs) conditionally
immortalized by introducing temperature-sensitive SV40-T anti-
gen by transfection has previously been characterized in detail
[18]. The GECs were maintained in the endothelial growth
medium 2 microvascular (EGM2-MV; LONZA, BE) containing
foetal calf serum (5%) and growth factors as supplied, at 33uC in
5% CO2. GECs differentiation was induced under nonpermissive
conditions by thermo shifting the cells to 37uC for 5–7 days. The
media was renewed every second day, and cells were split at
confluence approximately once a week using a trypsin-EDTA
solution (LONZA). Experiments were carried out with confluent
monolayers of cells cultured in 24-well plates (Nagle Nunc
International, Hereford, UK) with or without cover slips for
uptake studies, and in 75 cm2 culture flasks (Corning Incorporat-
ed, Corning, NY, USA) for the affinity purification experiment.
Immunofluorescence microscopy
Uptake of Alexa Fluor 546-labeled a-Gal A in cultured
human GECs. Recombinant a-Gal A was labeled with Alexa
Fluor 546 according to the instructions of the manufacturer
(Molecular Probes). Coverslips with GECs were incubated with
400 nM Alexa Fluor 546-labeled a-Gal A at 37uC at indicated
times, fixed with 4% paraformaldehyde for 10 min at room
temperature and counterstained with DAPI (Molecular Probes).
For co-localization with lysosomal compartments GECs were
incubated with Alexa Fluor 546-labeled a-Gal A and LysoTracker
Green DND-26 (L-7526; Molecular Probes) for 2 h.
Localization of proteins in GECs. Coverslips with GECs
were fixed with 2% paraformaldehyde, 4% sucrose in PBS for
10 min and with or without permeabilization with 0.3% Triton X-
100 (Sigma Aldrich) in PBS for 10 min. Nonspecific binding sites
were blocked with 4% FBS +0.1% Tween 20 (Sigma Aldrich) in
PBS for 60 min and the cells were incubated with primary
antibodies over night at 4uC. After this, they were incubated with
Alexa Fluor conjugated antibodies for 1 h at room temperature,
and nuclei-stained with DAPI. For co-localization of M6PR and
sortilin with a-Gal A, GECs were incubated with 400 nM Alexa
Fluor 546-labeled a-Gal A at 37uC for 1 h prior to localization of
the proteins.
All coverslips were mounted on glass slides in DAKO
Fluorescent Medium. Staining was analyzed by Zeiss confocal
laser scanning microscope. Controls for nonspecific binding were
performed with nonspecific serum and IgG fractions.
Protein extraction
Cell proteins were extracted by addition of modified RIPA
buffer (R-0278; Sigma Aldrich) containing complete protease
inhibitors (Roche Diagnostics, Mannheim, DE; 1 tablet per 50 ml
Figure 2. M6PR and sortilin bind specifically to a-Gal A in GECs. (A) Affinity chromatography indicate the migration of the different a-Gal A
binding proteins (arrowheads). (B) Western blot analysis demonstrated that the two bands were M6PR and sortilin. Lysate from human GECs culture
was used as a positive control.
doi:10.1371/journal.pone.0039975.g002
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of solution) at 4uC. The suspension was centrifuged at 14,000x g
for 15 min at 4uC, and the supernatant containing cellular protein
was collected. Total protein was quantified using Pierce BCA
Protein Assay kit (Pierce, Rockford, IL, USA) according to the
manufacturer.
Affinity purification of a-Gal A binding proteins
Purified recombinant a-Gal A was covalently coupled using the
AminoLink Plus Immobilization Kit (Pierce) following the
guidelines from the manufacturer. Affinity purification was done
as previously described [15]. Eluted Fractions were collected,
subjected to SDS-PAGE, and stained by silver staining using
SilverSNAP Stain Kit II (Pierce). Additional gels were blotted onto
PVDF membranes for further protein identification by Western
blotting.
SDS-PAGE and Western blotting
Eluted a-Gal A binding protein fraction with the highest protein
content and GECs lysates were loaded on the SDS-PAGE gels.
The samples were mixed with NuPAGE LDS sample buffer
(Invitrogen; Carlsbad, CA, USA) with 2.5% SDS, and the proteins
were separated by SDS-PAGE and electrophoretically transferred
to PVDF membranes (Millipore Corporation; Bedford, MA, USA)
for Western blot. Blots were blocked with 5% milk in PBS-T
(80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, and 0.1%
Tween 20 [pH 7.5]) for 1 h and incubated overnight at 4uC with
primary antibody in PBS-T with 1% BSA. After washing in PBS-
T, the blots were incubated for 1 h with horseradish peroxidase–
conjugated secondary antibody (DAKO). After a final wash,
antibody binding was visualized using ECL system (Amersham
International, Bucks, UK).
125I-labeled a-Gal A uptake by GECs
Recombinant a-Gal A was iodinated with the use of the
chloramine-T method [19], as previously described [15]. Human
GECs were incubated with approximately 20 nM 125I-a-Gal A for
different times. GECs were also incubated with different
concentrations of 125I-a-Gal A for 12 h at 37uC as indicated.
For uptake and inhibition studies, human GECs were incubated
with approximately 20 nM 125I-a-Gal A in the presence or
Figure 3. Immunofluorescent demonstration of sortilin, M6PR and PECAM-1 in cultured human GECs. (A) Non-permeabilized GECs
showing cell surface labeling of sortilin and M6PR. White arrowheads indicate potential cell surface labeling of the different receptors. (B)
Permeabilized GECs showing intracellular labeling for both M6PR and sortilin. (C) Demonstration of the specific endothelial cell marker PECAM-1 in
permeabilized GECs. (D) Endocytosed recombinant a-Gal A (red) co-localizes with both sortilin (green) and M6PR (green) in intracellular
compartments after 60 min. A high-power view of the co-localization of M6PR with recombinant a-Gal A is shown, yellow color indicated with white
arrowheads demonstrates co-localization. Controls were incubated with serum and detected with same secondary antibodies (data not shown).
Nuclei (blue) were stained with DAPI. Scale bars, 5 mm.
doi:10.1371/journal.pone.0039975.g003
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absence of 100 mM M6P, 10 mM RAP, 1 mM unlabeled a-Gal A,
and both M6P/RAP at 37uC for 12 h. Incubation with 125I-a-Gal
A was carried out in serum-free medium (EGM2-MV) containing
0.1% BSA (Sigma Aldrich), and stopped by aspiration of the
medium. Cells were washed in PBS and collected by trypsinization
with 150 ml of Trypsin-EDTA. The samples were counted in a c-
counter (Cobra 5003, Packard, Meriden, CT, USA). Degradation
was measured by precipitation of the medium in 10% TCA and
the TCA-soluble fraction, defined as the degraded fraction. To
correct for liberation per se of iodine from 125I-a-Gal A during the
Figure 4. Uptake of 125I-labeled a-Gal A by human GECs. (A and B) Human GECs were incubated with 125I-a-Gal A for different times at 37uC
showing both total and cell-associated a-Gal A uptake. (C and D) Human GECs were incubated with different concentrations of 125I-a-Gal A for 12 h at
37uC showing both total and cell-associated a-Gal A uptake. (E) Uptake of 125I-a-Gal A and inhibition with M6P, RAP, a combination of both M6P and
RAP, and a-Gal A. Uptake was assayed as described in the method section. Each point represents a mean of triplicates with standard deviations.
Addition of inhibitors show significant (*) reductions (P,0.002) in the uptake of a-Gal A after 12 h.
doi:10.1371/journal.pone.0039975.g004
Receptor-Mediated Endocytosis in Endothelial Cells
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experiment, the medium in control wells was incubated without
cells. Degradation was calculated as the TCA-soluble fraction in
the incubation medium minus the TCA-soluble fraction in the
medium from control wells. Cell-associated 125I-a-Gal A was
measured by counting the cells after trypsinization. Total uptake
was defined as the sum of degraded and cell-associated fraction
divided by the total amount of tracer added in each well. The
medium from control wells contained a TCA-soluble fraction of
approximately 5%.
Surface plasmon resonance
For the surface plasmon resonance (SPR) analyses, BIAcore
sensor chips (type CM5; BIAcore, Uppsala, SE) were activated as
previously described [16]. Recombinant human soluble M6PR
and sortilin were immobilized to densities 72 to 75 fmol/mm2.
The samples in flow buffer were injected and the binding data was
analyzed using the BIAevaluation program as previously described
[15].
Statistical analysis
The results of 125I- a-Gal A uptake experiments are presented as
means 6 SD, and the t test was used to test for significant
differences. P values ,0.05 were considered significant.
Results
Kidney endothelial cells take up recombinant a-Gal A
Using immunohistochemistry, we have previously shown that in
a classic male Fabry patient, a-Gal is not detectable [15]. Here, we
show for the first time that 2 hours after infusion of a-Gal A the
enzyme is detectable in GECs of a renal biopsy from a Fabry
patient (Figure 1A) and colocalizes with the endothelial cell surface
marker CD34 as demonstrated by double-immunofluorescence
staining. Immunoperoxidase staining also show that a-Gal A is
detectable in endothelial cells (ECs) of larger renal vessels in the
same Fabry patient after ERT (Figure 1B).
In conditionally immortalized human GECs [18], recombinant
a-Gal A is taken up in a time- dependent manner (Figure 1C). The
endocytosed enzyme was localized to the lysosomes as confirmed
by co-localization of Alexa-Fluor 546 conjugated a-Gal A with
LysoTracker-green (Figure 1D).
Isolation and identification of M6PR and sortilin as a-Gal
A-interacting proteins in GECs
Solubilized extract from cultured GECs was passed over either a
recombinant a-Gal A coupled resin or a control resin. Compar-
ison of the eluates from the two columns revealed that two protein
bands with apparent masses of 250 and 100 kDa were present in
the fractions eluted from the a-Gal A resin but not the control
resin (Figure 2A). To determine the identity of the proteins, the
eluted fractions were run on SDS-PAGE gel followed by
immunoblotting. The proteins were identified as M6PR and
sortilin using the corresponding antibodies (Figure 2B).
Cultured human GECs express sortilin and M6PR
Immunofluorescence studies demonstrated that both sortilin
and M6PR were expressed at the cell surface of cultured human
GECs (Figure 3A). The expression of sortilin and M6PR was also
demonstrated in permeabilized GECs showing prominent intra-
cellular labeling (Figure 3B), as would be expected for sorting
receptors. The phenotype of GECs was characterized by using a
specific endothelial antibody-marker to PECAM-1 under permea-
bilized conditions (Figure 3C). Recombinant a-Gal A taken up by
Figure 5. Binding of a-Gal A by M6PR and sortilin. The purified
ectodomains of M6PR and sortilin were immobilized on BIAcore chips.
(A) SPR analysis of a-Gal A binding to purified human M6PR. (B) Binding
of 50 nM a-Gal A to M6PR in the presence or absence of 50 mMM6P. (C)
Inhibition of a-Gal A binding to sortilin by M6PR. Sortilin was saturated
with M6PR prior to injection of a-Gal A. For comparison, sortilin was
saturated with flow buffer prior to injection of a-Gal A.
doi:10.1371/journal.pone.0039975.g005
Receptor-Mediated Endocytosis in Endothelial Cells
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GECs co-localize with both sortilin and M6PR in intracellular
compartments after 60 min (Figure 3D).
Sortilin and M6PR mediate specific uptake of a-Gal A in
human GECs
The endocytic activity of M6PR and sortilin expressed by
cultured human GECs was investigated by their ability to mediate
binding, internalization, and degradation of a-Gal A. 125I-a-Gal A
was bound, internalized, and degraded at 37uC (Figure 4A–4E).
The human GECs took up 125I-a-Gal A in both a time- and dose-
dependent manner (Figure 4A–4D). The uptake is shown as total
uptake including degradation products found in the medium
(Figure 4A and 4C) and cell associated uptake (Figure 4B and 4D).
Addition of M6P to the medium inhibited the a-Gal A uptake by
approximately 59% after 12 h and receptor associated protein
(RAP), which is well-known to inhibit the binding/uptake of
sortilin ligands [20], inhibited 29% after 12 h (Figure 4E).
Addition of excess unlabeled a-Gal A inhibited the uptake 53%
after 12 h (Figure 4E). Finally, the combined inhibition by M6P
and RAP was 76% after 12 h (Figure 4E).
Recombinant a-Gal A binds to human M6PR with very
high affinity
Surface plasmon resonance (SPR) analysis has already shown
that a-Gal A binds to sortilin with a Kd of 400 nM. SPR analyses
have also shown that recombinant a-Gal A binds to bovine
M6PR, here we show that a-Gal A binds to immobilized human
M6PR (41-1365aa) containing the two distinct M6P-binding sites
(repeating segments 3 and 9) [21] (Figure 5A). Using the
BIAevaluation program, Kd was estimated to 0.2 nM. We also
Figure 6. Expression of sortilin and M6PR in human GECs and in larger human renal vessel ECs. Dual immunofluorescence shows co-
localization of sortilin and M6PR with PECAM-1 in human GECs in the glomeruli (G) as seen in sections from a normal human kidney. The respective
merge images are shown in both low and high magnifications. Sortilin and M6PR are localized in the GECs and co-localizes with PECAM-1 to some
extent as seen by the merged images. High-power views demonstrate that the receptors are localized in the GECs as indicated with white
arrowheads. Sortilin and M6PR labeling of podocytes is also observed as previously shown in podocytes [15]. Scale bars, 20 mm. (B) Dual
immunofluorescence show co-localization of sortilin and M6PR with PECAM-1 and CD34 (EC cell surface markers), respectively. The receptors are
localized in the ECs of the larger renal vessels as indicated with white arrowheads. Staining of sortilin and M6PR is also seen in SMCs (blue
arrowheads). Scale bars, 25 mm.
doi:10.1371/journal.pone.0039975.g006
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examined if M6P inhibited the binding of a-Gal A to M6PR. At
50 mM, M6P markedly inhibited (,75%) the binding of a-Gal A
to M6PR (Figure 5B). We also tested the binding of a-Gal A to
immobilized M6PR (1510-2108aa), which contains the single IGF-
II-binding site (segment 11) [21], but no significant binding was
observed (data not shown). Furthermore, M6PR (41-1365aa) binds
to immobilized sortilin, and this binding prevents the binding of a-
Gal A to sortilin (Figure 5C) demonstrating that the binding of
M6PR (41-1365aa) to sortilin does not enhance a-Gal A binding
to the M6PR-sortilin receptor complex, as the binding is inhibited.
Expression of sortilin and M6PR in human kidney
endothelial cells
Immunohistochemistry revealed that sortilin and M6PR were
expressed in the ECs of normal human kidney (Figure 6A and 6B).
The antibodies have previously been shown to be specific, as
established by preabsorption of the two antibodies with their
respective antigens [15]. Immunofluorescence shows localization
of sortilin and M6PR in GECs as validated by co-localization with
PECAM-1 (Figure 6A). Immunofluorescence staining also showed
expression of sortilin and M6PR in the ECs of the larger renal
vessels (Figure 6B) as validated by co-localization with CD34 or
PECAM-1. Sortilin and M6PR were also expressed in SMCs of
the vasculature in the human kidney (Figure 6B).
Discussion
The present study was carried out to identify the mechanism of
a-Gal A uptake in human GECs. We found that infused
recombinant a-Gal A accumulated in the GECs and the uptake
was targeted to the lysosomes by the cation-independent M6PR
and sortilin. To our knowledge, none of these findings have been
reported previously in human GECs.
Vascular endothelial cells are one of the severely affected cells in
Fabry disease. [1] The mechanism by which this accumulation
causes symptoms of disease is still unknown. Enhanced vascular
thrombosis has been demonstrated [22,23,24], as well as altered
endothelial-dependent vascular reactivity [25,26,27], increased
markers of endothelial activation and endothelial microparticles
[28,29], and increased production of reactive oxygen species
[30,31,32] in patients with Fabry disease and in Fabry mouse
models. Endothelial dysfunction has been shown to lead to
prominent vasculopathy in patients with Fabry disease similar to
that of diabetic nephropathy [1,33]. The accumulation of GL-3 in
GECs, which together with the glomerular basement membrane
and podocytes, play a pivotal role in glomerular permeability and
selectivity, may predispose to albuminuria in Fabry disease
through direct effects on GECs.
ERT with recombinant a-Gal A was reported to clear the GL-3
deposits in a variety of ECs in patients with Fabry disease
[1,7,8,9,34,35]. However, the mechanism of GL-3 clearance in the
GECs and renal ECs has not been elucidated. Immunohisto-
chemical localization of recombinant a-Gal A showed that after
2 h of ERT, the recombinant a-Gal A was taken up by GECs and
renal ECs in a Fabry disease patient, but also in cultured human
GECs.
We identified sortilin and M6PR as responsible for the a-Gal A
uptake in GECs. Immunofluorescence analysis demonstrated for
the first time that sortilin and M6PR were expressed in the GECs
as verified by co-localization with PECAM-1 and CD34.
Furthermore, immunofluorescence and Western blot studies also
showed that the expression of these receptors could be detected in
cultured human GECs. We have previously described that a-Gal
A bound to sortilin with high affinity and was involved in the
receptor-mediated uptake of recombinant a-Gal A in human
podocytes and HEK293 cells transfected with sortilin [15]. In this
study we show for the first time that a-Gal A binds to the human
M6PR through the M6P-binding sites with very high affinity, but
does not bind to the IGFII-binding site on M6PR. Sortilin is a
multifunctional lysosomal receptor belonging to the Vps10p
domain receptor family and homologous to that of the M6PR
[36,37]. Thus, M6PR and sortilin are sorting receptors typically
found in intracellular compartments of the trans-Golgi network
and early endosomes and have roles in both endocytosis and
intracellular trafficking of proteins [37,38,39,40]. However, we
cannot discard the possibility that other pathways may exist as well
for the cellular uptake of a-Gal A in the GECs and renal ECs,
probably some form of fluid phase endocytosis may take place.
Recombinant a-Gal A binds to M6PR with higher affinity than
to sortilin. We have previously shown that a-Gal A binds to sortilin
with a Kd of 400 nM. In this study we show that a-Gal A binds to
M6PR with a higher affinity, Kd of 0.2 nM. Recombinant a-Gal A
binds to sortilin on the Vps10p-domain, as the binding and uptake
of a-Gal A by sortilin can be inhibited by neurotensin, RAP and
sortilin propeptide [15]. This is further supported by a study that
reveals the crystal structure of sortilin ectodomain in complex with
neurotensin. Here authors show that neurotensin binds to sortilin
in the tunnel of a ten-bladed b-propeller domain [41]. The
M6PR/IGF-IIR contains three binding sites; two M6P-binding
sites and one IGF-II [21]. Recombinant a-Gal A binds to the
M6P-binding sites and not to the IGF-II binding site as shown by
the BIAcore studies. This supports the suggestion that a high
number of M6P moieties on a-Gal A [42] would improve the
uptake and delivery of a-Gal A to different cells by the M6PR.
Identification of M6PR and sortilin in human GECs further-
more suggests that, under physiological conditions, these receptors
could be involved in the uptake of constituents from the plasma.
Finally, M6PR and sortilin may be involved in sorting and
signaling in GECs [37]. The expression of sortilin in both GECs
and podocytes suggest that sortilin may be involved in new
signaling cascades important for communication between these
closely associated cells.
The delivery of a-Gal A to other ECs such as the macrovascular
ECs, which are phenotypically and functionally different from
microvascular ECs [43,44], has not been tested. The EC-types
show great variability [45]. However, we have shown that sortilin
and M6PR were highly expressed in both larger vessels and
capillaries in the kidney. Thus the receptors may have similar
functions in microvascular and macrovascular systems.
In conclusion, these data demonstrate that M6PR and sortilin
were expressed in human GECs and mediated the uptake of
recombinant a-Gal A. We also show that sortilin and M6PR were
expressed in the ECs of the larger vessels of the kidney. Thus we
provide evidence of an additional receptor, sortilin, to the general
M6PR in ECs cells for the delivery of therapeutic recombinant a-
Gal A in Fabry disease and potentially other lysosomal storage
disorders.
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